Genocea Biosciences (NASDAQ:GNCA) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.05, Fidelity Earnings reports.
Shares of GNCA traded down $0.08 during trading hours on Friday, reaching $2.10. The company’s stock had a trading volume of 313,427 shares, compared to its average volume of 185,207. The firm has a market cap of $56.87 million, a price-to-earnings ratio of -1.11 and a beta of 2.51. Genocea Biosciences has a 1-year low of $1.99 and a 1-year high of $11.28. The company has a quick ratio of 4.33, a current ratio of 4.33 and a debt-to-equity ratio of 0.45. The company has a 50 day moving average of $2.23 and a two-hundred day moving average of $2.63.
A number of research firms have commented on GNCA. ValuEngine raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Genocea Biosciences in a research note on Monday, November 11th. Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Leerink Swann began coverage on Genocea Biosciences in a report on Friday, November 15th. They issued an “outperform” rating on the stock. Finally, Svb Leerink began coverage on Genocea Biosciences in a report on Friday, November 15th. They issued an “outperform” rating and a $7.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $12.94.
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Featured Story: What is the significance of the death cross?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.